#AHA 21 Learning Studios
Plan your schedule now with this comprehensive list of educational sessions during Scientific Sessions 2021.
Learning Studios current as of Oct. 20, 2021
Saturday, Nov. 13
The Heart of the Matter: A New Treatment for Slowing CKD Progression and Reducing CV Risk in Patients With CKD Associated With T2D
Recent advancements in clinical understanding of CKD associated with T2D and accompanying cardiovascular risk have informed new treatment options and strategies for disease management. This event will showcase a new prescription treatment for CKD associated with T2D and present clinical safety and efficacy data for this treatment. How to identify appropriate adult patients with CKD associated with T2D and how to initiate treatment will also be discussed. After the presentation, there will be an opportunity for Q&A.
Supporter: Bayer HealthCare Pharmaceuticals Inc.
Heart Failure Isn’t the Only Type of "Failure" in Cardiology: Raising the Clinical Suspicion for Hypertrophic Cardiomyopathy (HCM)
Experts will explore challenging HCM patient cases, highlight clinical findings that should raise the index of suspicion for HCM among alternative diagnoses and discuss available imaging modalities and additional resources to help eliminate HCM misdiagnosis altogether
Supporter: Bristol Myers Squibb
11 a.m.-12:30 p.m.
Potential Impact of Virtual Longitudinal Studies
Mobile devices, wearable technology and easier patient access to health records provide opportunities for scaled, decentralized research that captures data from a host of different sources. The use of technology removes barriers to participation, increases access to traditionally under-represented groups, and results in the seamless generation and collection of data. With that in mind, AHA will bring together key thought leaders in the cardiovascular and digital health space to discuss the changing landscape of virtual trials and studies, along with the benefits and challenges in accelerating research and ultimately improving health outcomes.
Supporter: Center for Health Technology and Innovation
A Focus on Very High-Risk Patients in the Acute Setting: Understanding Vulnerable Plaque and Prioritizing LDL-C
In this presentation, Dr. Michael Blaha will discuss the importance of cholesterol management in very high-risk ACSVD patients in the acute setting and focus on plaque vulnerability and the role of LDL-C. Don’t miss this informative presentation and discussion of a treatment option.
Supporter: Amgen Cardiovascular
Jardiance® (empagliflozin) Tablets: A Review of the Latest Data
This program will review recent clinical trial data for JARDIANCE. It will also provide information on JARDIANCE initiation and dosing as well as guidance for monitoring patients on JARDIANCE. Attendees will have the opportunity to ask the faculty questions about the data presented.
Supporter: Boehringer Ingelheim/Lilly, USA
Your Elderly Heart Failure Patient: Considerations, Management and Future Directions
This program shares the geriatrician’s perspective on chronic heart failure. Key discussion topics include an overview of the epidemiology and disease course of heart failure in elderly patients as well as an update on considerations for comorbidities, management and future directions for clinical practice and research.
Supporter: Novartis Pharmaceuticals Corporation - Medical Affairs
1:45-2:15 p.m. | Roundtable
What's New When it Comes to Diagnosing and Treating Hypertrophic Cardiomyopathy Patients
Join leading experts to learn how the 2020 Hypertyrophic Cardiomyopathy (HCM) Guideline Update impacts the diagnostic and treatment options for patients, including what new treatments are on the horizon. Panelists will share their experience and insights, including highlights from AHA's HCM initiative aiming to establish and advance a new standard of care for patients with HCM.
Supporter: Bristol Myers Squib
Clinical Insights in CAD and/or PAD: Reducing the Risk of Major Cardiovascular Events
Patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD) are at risk for major cardiovascular events, including cardiovascular death, myocardial infarction and stroke. This lecture will discuss an approach to reducing the risk of these events.
Supporter: Janssen Pharmaceuticals, Inc.
Opportunities to Improve Health Outcomes in ASCVD: A Focus on Population Health and a Call to Action for Health Equity
This disease state education program will focus on strategies to improve health outcomes in atherosclerotic cardiovascular disease (ASCVD). Key discussion topics will include an update on the prevalence and disease burden of ASCVD, exploring/differentiating population health approaches to optimize the primary and secondary prevention of ASCVD and a call to action to promote health equity and improve outcomes for ASCVD in the United States.
Supporter: Novartis Pharmaceuticals Corporation - Medical Affairs
NHLBI Company Showcase
The American Heart Association (AHA) and the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) are convening at this year’s Scientific Sessions to host a live virtual pitch exhibition featuring six NHLBI-funded companies. Attendees will have the opportunity to learn about the latest innovative cardiovascular technologies from each company. These companies are part of a larger portfolio of companies that are supported by the NHLBI Small Business Program, and will receive funding, coaching and partnering support as part of this program. After the session, attendees will be able to network and engage with each company.
Sunday, Nov. 14
Implementing GDMT in Worsening Heart Failure Patients – Easy or Challenging? A Debate
This session will explore the complexities of implementing GDMT in patients with worsening heart failure. Your peers will identify key clinical challenges and best practices, as well as discuss specific patient types that pose greater challenges to GDMT implementation. This will be followed by a spirited, collegial debate about the “ease” of implementing GDMT. A brief review of the new universal definition of heart failure and its new classification will set the stage for this lively debate.
Supporter: Cytokinetics, Inc.
Add on Efficacy. Oral, Nonstatin Therapies for Lowering LDL-C
The session will cover the following information:
• Atherosclerotic cardiovascular disease and lipid management
• Unique mechanism of action for two treatment options
• Efficacy data for two treatment options
• Safety data for two treatment options
• Overview of the ongoing Outcomes trial
Supporter: Esperion Therapeutics, Inc.
Clinical Insights in NVAF: Reducing the Risk of Stroke and Systemic Embolism
Patients with nonvalvular atrial fibrillation (NVAF) are at risk of stroke. This lecture will present options for reducing the risk of stroke in patients with NVAF and in patients with NVAF and obesity.
Supporter: Janssen Pharmaceuticals, Inc.
Double Trouble: AF & HF
Following a deteriorating spiral of disease progression, heart failure (HF) and atrial fibrillation (AF) can present a significant public health challenge. Early rhythm control in AF can improve clinical outcomes, including among AF patients with HF. Unfortunately, siloed care leaves many patients undiagnosed and untreated. Join Drs. Jagmeet Singh and Javed Butler as they discuss exciting new data on the management of these patients and how to bridge the clinical divide to improve patient care.
Cholesterol Efflux Hypothesis: Rethinking Good Cholesterol
CSL Behring is pleased to support the 2021 AHA Scientific Sessions Learning Studio, titled "Cholesterol Efflux Hypothesis: Rethinking Good Cholesterol." Chair Prof. Roxana Mehran will facilitate presentations and discussion with Prof. Gilles Montalescot and Prof. Dominick Angiolillo. The experts will discuss the risk of early recurrent CV events and the unmet need in the 90-day high-risk period following a heart attack, along with the relationship between cholesterol efflux capacity and CV outcomes.
Supporter: CSL Behring
The Journey to Diagnosis: Recognizing the Signs and Symptoms of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Transthyretin amyloid cardiomyopathy (or ATTR-CM) is an underrecognized and underdiagnosed disease that leads to heart failure. This presentation from a leading expert will provide an overview of ATTR-CM and highlight how to recognize the signs and symptoms that raise suspicion of ATTR-CM, while introducing approaches to achieve an appropriate diagnosis. The program will end with a review of the clinical data for a treatment option for ATTR-CM.
Supporter: Pfizer, Inc.
Diagnosing Aortic Stenosis in Women to Close the Treatment Gap
Despite medical advancements, gender disparities prevail regarding diagnosis and treatment for Valvular Heart Disease. With a focus on Aortic Stenosis, Dr. Pam Taub will use an evidence-based approach and patient examples to highlight the gender treatment gap. Dr. Taub will also cover the need for early detection in alignment with the latest ACC/AHA guidelines and share practical examples to help overcome barriers that impede timely intervention for women.
Learning Studio discussion also includes SMART Trial details.
Evolving the Chronic Heart Failure Treatment Paradigm in Cardiology
This program will use a case-based approach to review the clinical impact of recent developments in the treatment of chronic heart failure.
Supporter: Novartis Pharmaceuticals Corporation
VASCEPA® (icosapent ethyl): Elevating the Standard of Care
There is an urgency to treat Persistent Cardiovascular Risk (P-CVR) as it remains high despite statin-based standard-of-care therapy in patients with elevated triglycerides. In this program, we will review data from a practice changing trial that provides a groundbreaking therapeutic option to elevate the current standard of care.
Supporter: Amarin Pharma, Inc.
Monday, Nov. 15
How the Democratization of Fitness Can Improve Health Outcomes
Supporter: Planet Fitness, Inc.
A Treatment Option for Patients With HFrEF Following a Worsening HF Event
• Highlight the burden of HFH in patients with HFrEF
• Review a treatment option for reducing the risk of HFH and CV death in patients with HFrEF
Supporter: Merck & Co., Inc.
Comprehensive & Expanding: Overview of MEDTRONIC’s SYPRAL-HTN Global Clinical Trial Program
Attend this session if you want to:
• Understand the latest clinical evidence from the SPYRAL-HTN OFF MED and SPYRAL-HTN ON MED
• Learn more about the long-term durability and safety of renal denervation in a real-world patient population
• Review the latest guidance from key US scoieities regarding renal denervation with the experts
These events are not part of the official Scientific Sessions 2021 as planned by the AHA Committee on Scientific Sessions Programming.